The Sample Distribution and Banking Core (Part A) serves to provide clinical bone marrow, pheresis and peripheral blood sample to the various projects. A well established system is in place with centralized sample, collection, processing, processing, distribution, banking, and databank/record keeping. Samples are processed to yield serum, protein whole cell lysates, DNA, RNA, cells, and granulocyte fractions. A shift to perform magnetic antibody cell sorting (MACS) to separate leukemic from non-leukemic cells was recently implemented thereby allowing the core to provide a purer production. Dependent on project requirements, fresh or stored material is delivered to all projects and cores B and C of this grant. Protocols for the equitable distribution of scare materials are also in place. The core maintains an up to date database of all the materials that are available to the overall project database. The core maintains an up to data database of all the materials that are available that is attached to the overall project database. Project investigators can search this database over the secured network to identify available archival material of interest. The Cell Culture Core (Part B) will provide cell culture support for this Program Project. The assays we use can detect hematopoietic progenitors at various levels of differentiation and can distinguish between normal and neoplastic colony-forming cells. These assays are well suited to address a major issue arising in this program project, namely the derivation of the cells responding to various specific agents investigated in this PO-1 on normal Vs leukemic early and mature progenitors. We will use the in vitro assays to determine the effect of specific kinase inhibitors as outlined in Project 1) on leukemic and normal (early an mature) progenitors. We will also use the experimental system to test the in vitro effects of various nucleoside analogues and without kinase inhibitors and inhibitors of Cdk2 phosphorylation as presented in Project 3. The Cell culture core will also support the work proposed in Project 4 by examining whether genetic abnormalities detected at locus 7q31.1 exist both in early and mature progenitors. Dr. Zeez Estrov will direct part B and Steven Kornblau will direct part A and serve as overall core director.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA055164-10A1
Application #
6479181
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1992-06-01
Project End
2005-06-30
Budget Start
Budget End
Support Year
10
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Jiang, Xuejie; Mak, Po Yee; Mu, Hong et al. (2018) Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res 24:2417-2429
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Sekihara, Kazumasa; Saitoh, Kaori; Han, Lina et al. (2017) Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget 8:34552-34564
Carter, Bing Z; Mak, Po Yee; Wang, Xiangmeng et al. (2017) Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther 16:1133-1144
Zeng, Zhihong; Liu, Wenbin; Tsao, Twee et al. (2017) High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica 102:1537-1548
Pan, Rongqing; Ruvolo, Vivian; Mu, Hong et al. (2017) Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell 32:748-760.e6
Jacamo, Rodrigo; Davis, R Eric; Ling, Xiaoyang et al. (2017) Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget 8:83354-83369

Showing the most recent 10 out of 422 publications